Search clinical trials for: thyroid carcinoma

Total 31639 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
University College, London
Cancer Research UK

Active, not recruiting

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients (IoN)

Thyroid Cancer

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland...

United States
TransThera Sciences (Nanjing), Inc.

Completed

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Sarcoma | Gastric Cancer | Prostate Cancer | Cholangiocarcinoma | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Small-cell Lung Cancer | Thyroid Cancer | Gallbladder Cancer | HER2-negative Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Castleman Disease | Lymphangioleiomyomatosis | Digestive System Carcinoma | Malignant Neoplasm | Recurrent Breast Carcinoma | Recurrent Thyroid Gland Carcinoma | Metastatic Urothelial Carcinoma | Malignant Female Reproductive System Neoplasm | Neurofibromatosis Type 2 | Recurrent Adult Soft Tissue Sarcoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma

United States
Fujian Medical University

Completed

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Thyroid Cancer, Anaplastic

China
Jiangxi Provincial Cancer Hospital

Completed

Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients

Thyroid Neoplasms

China
University Medical Center Groningen
Erasmus Medical Center

Completed

Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging (TARGET)

Papillary Thyroid Cancer | Lymph Node Metastases

Netherlands
Jiangxi Provincial Cancer Hospital

Completed

Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer

Thyroid Neoplasms
Hoffmann-La Roche

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Endocrine System Diseases | Gastrointestinal Neoplasms | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Respiratory Tract... and other conditions

France, Spain, United States, Korea, Republic of, United Kingdom, Taiwan, China, Belgium, Singapore, Netherlands, Germany, Italy, Hong Kong
Radboud University Medical Center

Completed

Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma (DIGUP-TC)

Non-Medullary Thyroid Carcinoma

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Recurrent Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditions

United States
Hoffmann-La Roche

Active, not recruiting

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)

Solid Tumors | CNS Tumors

United States, Spain, Korea, Republic of, Canada, Germany, United Kingdom, China, Italy, Hong Kong, France, Taiwan
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Differentiated Thyroid Cancer

China
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Carcinoma, Non-Small-Cell Lung | Thyroid Neoplasms

United States
Saint Petersburg State University, Russia

Withdrawn

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)

Thyroid Gland Anaplastic Carcinoma

Russian Federation
Chinese PLA General Hospital

Completed

Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma

Papillary Thyroid Cancer
Saint Petersburg State University, Russia

Withdrawn

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

Russian Federation
Exelixis
Ipsen

Active, not recruiting

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Differentiated Thyroid Cancer

Hong Kong, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Croatia, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Taiwan, ... and more
National Cancer Center Hospital East
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Anaplastic Thyroid Cancer

Japan
National Taiwan University Hospital

Completed

Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3

Thyroid Cancer

Taiwan
Istituti Clinici Scientifici Maugeri SpA
University of Pavia; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Completed

Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy (CAPABLE-IT)

Stomach Cancer | Breast Cancer | Head and Neck Cancer | Lung Cancer | Thyroid Cancer | Renal Cell Carcinoma Metastatic | Ovary Cancer

Italy
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer... and other conditions

United States, Canada
SOTIO Biotech AG
SOTIO Biotech a.s.

Active, not recruiting

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions

United States, France, Spain, Czechia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Differentiated Thyroid Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Thyroid Gland Medullary Carcinoma | Differentiated Thyroid Gland Carcinoma | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321)

Solid Tumor | Medullary Thyroid Cancer

China
Jonsson Comprehensive Cancer Center

Suspended

Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer

Thyroid Gland Carcinoma | Thyroid Gland Nodule

United States
Memorial Sloan Kettering Cancer Center

Completed

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Thyroid Cancer, Papillary | Thyroid Cancer, Follicular | Thyroid Carcinoma | Thyroid Cancer | Thyroid Cancer (Follicular Cell) | BRAF V600E Mutation Positive

United States
UNICANCER
Merck Sharp & Dohme LLC; National Cancer Institute, France; Ligue contre le cancer...

Completed

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types (AcSé)

Sarcoma | Neoplasms, Germ Cell and Embryonal | Carcinoma, Neuroendocrine | Ovarian Neoplasm | Central Nervous System Neoplasm | Thyroid Neoplasm | NK/T-cell Lymphoma

France
Eli Lilly and Company
Loxo Oncology, Inc.

No longer available

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Carcinoma, Non-Small-Cell Lung | Thyroid Neoplasms
Stanford University

Active, not recruiting

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Thyroid Cancer | Anaplastic Thyroid Cancer | Undifferentiated Thyroid Cancer

United States
Helsinki University Central Hospital

Active, not recruiting

a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS

to Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Breast Cancer | Pancreatic Cancer | Lung Cancer | Rectal Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Colon Cancer | Gastrointestinal Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Thyroid Gland Medullary Carcinoma | Liver and Intrahepatic Biliary Tract Cancer

United States
Hutchmed
BeiGene

Active, not recruiting

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors | Metastatic Solid Tumor | Anaplastic Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Recurrent Thyroid Gland Medullary Carcinoma | Hereditary Thyroid Gland Medullary Carcinoma | Locally Advanced Thyroid Gland Medullary Carcinoma | Sporadic Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary... and other conditions

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma? (DSR-MTC)

Medullary Thyroid Cancer | Lymph Node Disease | Lymph Node Metastasis | Medullary Carcinoma | Medullary Tumor | Medullary Neoplasms | Desmoplasia | Desmoplastic | Desmoplastic Reaction

Italy
JS InnoPharm, LLC

Suspended

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Solid Tumors

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Kidney Medullary Carcinoma | Loss of INI 1 Protein Expression

United States
Vanderbilt-Ingram Cancer Center

Terminated

Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System

Thyroid Carcinoma | Radioactive Iodine Level

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.

Completed

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Thyroid Cancer | Differentiated Thyroid Cancer | Anaplastic Thyroid Cancer

United States
Hoffmann-La Roche

Withdrawn

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)

Medullary Thyroid Cancer

Spain
National Cancer Institute (NCI)

Completed

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Thyroid Gland Carcinoma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Thyroid Gland Medullary Carcinoma

United States, Canada
Johns Hopkins University

Active, not recruiting

Radiofrequency Ablation of Papillary Thyroid Microcarcinoma

Papillary Thyroid Cancer

United States
University College, London

Active, not recruiting

High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer (HiLo)

Head and Neck Cancer

United Kingdom

Search clinical trials for: thyroid carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations